1. Home
  2. HBIO vs BRNS Comparison

HBIO vs BRNS Comparison

Compare HBIO & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.11

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

HOLD

Current Price

$0.63

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
BRNS
Founded
1901
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
24.1M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
HBIO
BRNS
Price
$6.11
$0.63
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$18.00
$4.00
AVG Volume (30 Days)
12.7K
38.9K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,176,000.00
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$8.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.51
52 Week High
$7.50
$2.91

Technical Indicators

Market Signals
Indicator
HBIO
BRNS
Relative Strength Index (RSI) 46.83 52.44
Support Level $5.91 $0.65
Resistance Level $6.70 $0.75
Average True Range (ATR) 0.28 0.05
MACD -0.03 0.00
Stochastic Oscillator 9.76 62.94

Price Performance

Historical Comparison
HBIO
BRNS

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: